Medpace Holdings, Inc.

Medpace Holdings, Inc. (NASDAQ: MEDP) is one of the world's leading clinical contract research organizations solely focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company's website is www.medpace.com.

Medpace operates a comprehensive, full-service clinical development platform spanning Phase I through Phase IV trials across major therapeutic areas including Oncology, Metabolic, Cardiology, Antiviral and Anti-infective, and Central Nervous System. The company differentiates itself through its disciplined operating model and deep therapeutic expertise, positioning itself as a partner of choice particularly for small and mid-sized biopharmaceutical companies seeking timely and cost-effective clinical development services.

The company's service offerings encompass the complete clinical trial lifecycle, including medical department oversight, clinical trial management through its proprietary ClinTrak information system, data-driven feasibility analysis, study start-up coordination, patient recruitment and retention, clinical monitoring, regulatory affairs guidance, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory services, central laboratory operations, bioanalytical laboratory services, clinical research clinics, and quality assurance. Medpace maintains central laboratory facilities in Cincinnati Ohio, Leuven Belgium, Shanghai China, and Singapore, along with clinical research campuses and operations across 46 countries.

As of December 31, 2025, Medpace employed approximately 6,200 associates globally, with approximately 66 percent of employees being women and 65 percent of management positions held by women. The company maintains a well-diversified customer base spanning small biopharmaceutical companies, mid-sized biopharmaceutical companies, and large pharmaceutical companies. Medpace's business model emphasizes full-service outsourcing capabilities, therapeutic expertise, and a consultative sales approach that integrates medical and scientific experts throughout the customer engagement process. The company competes against other full-service CROs and in-house research and development departments, competing primarily on therapeutic area experience, staff quality, service reliability, range of services, investigator and patient recruitment capabilities, global presence, speed to completion, and overall value proposition.